• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Patritumab Deruxtecan in EGFR-mutated NSCLC post EGFR TKI and Chemotherapy

byDaniel GoldshteinandSze Wah Samuel Chan
September 18, 2023
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The objective response rate was 29.8% (1% complete response, 66% partial response) with a PFS of 5.5 months and a median OS of 11.9 months.

2. 64.9% of treatment-emergent adverse events (TEAEs) of grade ≥3, in which thrombocytopenia and neutropenia were the most common.

Evidence Rating Level: 2 (Good)

Study Rundown: Salvage therapy is limited for patients with EGFR-mutated advanced NSCLC who have failed the typical initial treatment with EGFR TKIs and second-line platinum-based chemotherapy. However, it was found that HER3, a protein linked to resistance to EGFR TKIs, is prevalent in NSCLC tumours, and a recent experimental therapy targeting HER3, Patritumab deruxtecan (HER3-DXd), showed initial promise in a phase I study. This is a phase II trial that evaluates HER3-DXd in EGFR-mutated NSCLC patients who previously failed EGFR TKI therapy and platinum-based chemotherapy. The primary endpoint was confirmed objective response rate (ORR) as either complete response or partial response. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety. The confirmed ORR was 29.8%, with 1% complete response and 66% partial response. The median duration of response was 6.4 months. The median PFS was 5.5 months and the median OS was 11.9 months. Outcome measures were similar in patients with and without central nervous system (CNS) metastases. Biomarkers were also analyzed and found that confirmed ORR ranged from 27.3% in patients with no identified EGFR TKI resistance associated genes, to 37.5% in patients with both EGFR dependent and independent resistance mechanisms. With regards to safety, there were 64.9% treatment-emergent adverse events (TEAEs) of grade ≥3, and 28.9% TEAEs of grade ≥4. The most common grade ≥3 TEAEs were thrombocytopenia (20.9%) and neutropenia (19.1%). TEAEs were associated with dose interruption in 40.4% of patients, dose reduction in 21.3%, and treatment discontinuation in 7.1%. The strengths of this study included a larger patient size compared to phase 1, and the limitations included a lack of a control arm. Overall, this study found some efficacy of HER3-DXd in patients with EGFR-mutated NSCLC who had previously failed EGFR TKI therapy and platinum-based chemotherapy.

Click to read the study in JCO

Relevant Reading: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

RELATED REPORTS

Taletrectinib in ROS1 mutated Non–Small Cell Lung Cancer

Neoadjuvant Nivolumab/Ipilimumab Vs Chemotherapy in Resectable NSCLC

RAMOSE Phase II trial finds promising results for osimertinib and ramucirumab in non-small cell lung cancer

In-Depth [prospective cohort]: This multicenter, open-label, phase II trial investigated previously treated patients with advanced EGFR-mutated NSCLC (exon 19 deletion or L858R), who received at least one EGFR TKI (mostly Osimertinib) and at least one platinum-based chemotherapy, into two dose schedules of HER3-DXd once every three weeks, a fixed-dose regimen (226 patients), and an uptitration regimen (51). The uptitrated regimen arm was closed after the risk/benefit was found to be similar to the phase 1 trial. These results are for the fixed-dose regimen. The median duration of follow-up was 19.8 months. It was found that ORR was 29.8% (95%CI, 23.9 to 36.2), with 1% complete response and 66% partial response. Median duration of response was 6.4 months (95%CI, 4.9 to 7.8). Median PFS was 5.5 months (95%CI, 5.1 to 5.9) and median OS was 11.9 months (95%CI, 11.2 to 13.1). The uptitrated arm had confirmed ORR 16.0% (95%CI, 7.2 to 29.1) and PFS was 6.7 months (95%CI, 4.2 to 8.8). Outcome measures were similar in patients with and without central nervous system (CNS) metastases, and a separate analysis of 30 patients with CNS metastases at baseline found the CNS ORR was 33.3% (95%CI, 17.3 to 52.8). Biomarkers were also analyzed from 193 patients with evaluable tumor tissue, and found that confirmed ORR ranged from 27.3% in patients with no identified EGFR TKI resistance–associated genes, to 37.5% in patients with both EGFR dependent and independent resistance mechanisms. With regards to safety, there were 64.9% treatment-emergent adverse events (TEAEs) of grade ≥3, and 28.9% TEAEs of grade ≥4. Most common grade ≥3 TEAEs were thrombocytopenia (20.9%) and neutropenia (19.1%) and median time to first onset was 8 and 21 days respectfully. TEAEs were associated with dose interruption in 40.4% of patients, dose reduction in 21.3%, and treatment discontinuation in 7.1%. Overall, this study found some efficacy of HER3-DXd in patients with EGFR-mutated NSCLC who had previously failed EGFR TKI therapy and platinum-based chemotherapy.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: EGFR NSCLCnsclcPatritumab Deruxtecan
Previous Post

Atezolizumab is a potentially effective treatment option for patients with alveolar soft part sarcoma

Next Post

Generic and brand-name fluticasone-salmeterol are equally effective in COPD management

RelatedReports

Fluorophores enhance visualization for image-guided surgery [PreClinical]
Chronic Disease

Taletrectinib in ROS1 mutated Non–Small Cell Lung Cancer

April 7, 2025
Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant Nivolumab/Ipilimumab Vs Chemotherapy in Resectable NSCLC

January 13, 2025
Lessons from real-world implementation of lung cancer screening
Oncology

RAMOSE Phase II trial finds promising results for osimertinib and ramucirumab in non-small cell lung cancer

December 10, 2024
#VisualAbstract Amivantumab Plus Lazertinib Improves Survival in EGFR-mutated Advanced NSCLC
StudyGraphics

#VisualAbstract Amivantumab Plus Lazertinib Improves Survival in EGFR-mutated Advanced NSCLC

December 6, 2024
Next Post
2 Minute Medicine Rewind May 20, 2019

Generic and brand-name fluticasone-salmeterol are equally effective in COPD management

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

Rectal cancer presentation and screening rates during the COVID-19 pandemic

High dose antidepressants may increase self-harm risk among children, young adults

Adverse childhood experiences and current life stressors may moderate the relationship between depression and C-reactive protein in midlife women

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients
  • Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms
  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.